IRB Role In Clinical Trials Registries Should Be Limited To Checking Documentation, White Paper Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Making institutional review board approval of clinical studies contingent on placement of a study in a clinical trial registry would be an effective mechanism to enforce registry requirements, but the IRB role should be limited to verifying that the study has been submitted, the Fordham Center for Ethics Education suggests in a Sept. 2 white paper.
You may also be interested in...
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.
AstraZeneca Collaborations Moving From “Deals” To “Relationships”
Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.
Pharmacogenetic Dosing Recommendations Sorely Needed By Clinicians, Formularies, SACGHS Says
Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.